Futures
Hundreds of contracts settled in USDT or BTC
TradFi
Gold
Trade global traditional assets with USDT in one place
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Futures Kickoff
Get prepared for your futures trading
Futures Events
Participate in events to win generous rewards
Demo Trading
Use virtual funds to experience risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and enjoy airdrop rewards!
Futures Points
Earn futures points and claim airdrop rewards
Investment
Simple Earn
Earn interests with idle tokens
Auto-Invest
Auto-invest on a regular basis
Dual Investment
Buy low and sell high to take profits from price fluctuations
Soft Staking
Earn rewards with flexible staking
Crypto Loan
0 Fees
Pledge one crypto to borrow another
Lending Center
One-stop lending hub
VIP Wealth Hub
Customized wealth management empowers your assets growth
Private Wealth Management
Customized asset management to grow your digital assets
Quant Fund
Top asset management team helps you profit without hassle
Staking
Stake cryptos to earn in PoS products
Smart Leverage
New
No forced liquidation before maturity, worry-free leveraged gains
GUSD Minting
Use USDT/USDC to mint GUSD for treasury-level yields
Hong Kong Stock Connect | JD Health (06618) opens more than 3% higher after earnings, annual attributable profit up 29.16% year-on-year, "medical testing, diagnosis, and pharmaceuticals" closed-loop further improved
Reuters Finance APP reports that JD Health (06618) opened more than 3% higher after earnings release. As of the latest update, it rose 3.58% to HKD 49.2, with a trading volume of HKD 17.0767 million.
In terms of news, on March 5, JD Health announced its annual results for the year ending December 31, 2025. The group achieved revenue of 73.441 billion RMB, a 26.3% increase year-over-year; net profit attributable to shareholders was 5.375 billion RMB, up 29.16% year-over-year; basic earnings per share were 1.7 RMB. During the reporting period, JD Health further expanded its advantage as the “first stop for new drug launches online,” with over 100 new drugs launched throughout the year—significantly more than in 2024—demonstrating the company’s efficient pharmaceutical supply chain and professional service capabilities as core competitive advantages.
By 2025, JD Health will further improve the “medical-examination-prescription” service loop, continue to strengthen integrated online and offline healthcare services, and enhance specialized capabilities in dermatology, mental health, and chronic disease management through JD Internet Hospitals. JD Daojia’s rapid testing services have expanded to 27 cities nationwide, offering over 160 home testing services. Additionally, JD Health leverages AI technology to optimize intelligent consultation and health management products, improving service accuracy and accessibility, and building a professional, efficient full-scenario health service system.